Medtronic (NYSE:MDT) Releases Q2 2027 Earnings Guidance

Medtronic (NYSE:MDT) updated its second quarter 2027 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 1.320-1.340 for the period, compared to the consensus estimate of 1.350. The company issued revenue guidance of -. Medtronic also updated its FY 2027 guidance to 5.940-6.000 EPS.

Medtronic Stock Performance

Shares of MDT opened at $91.92 on Wednesday. The company has a quick ratio of 1.62, a current ratio of 2.13 and a debt-to-equity ratio of 0.52. The business’s 50 day moving average price is $86.03 and its 200-day moving average price is $85.42. Medtronic has a 52 week low of $73.31 and a 52 week high of $106.33. The stock has a market cap of $117.66 billion, a P/E ratio of 24.64, a P/E/G ratio of 2.43 and a beta of 0.56.

Medtronic (NYSE:MDT) last released its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 EPS for the quarter, topping the consensus estimate of $1.39 by $0.06. The company had revenue of $9.76 billion during the quarter, compared to the consensus estimate of $9.55 billion. Medtronic had a return on equity of 14.51% and a net margin of 13.20%.Medtronic’s revenue for the quarter was up 13.7% on a year-over-year basis. During the same period last year, the company earned $1.26 EPS. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. Equities research analysts anticipate that Medtronic will post 5.94 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 16th. Stockholders of record on Friday, September 25th will be paid a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 3.1%. The ex-dividend date is Friday, September 25th. Medtronic’s dividend payout ratio (DPR) is currently 77.21%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. Wall Street Zen upgraded Medtronic from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. The Goldman Sachs Group cut their price target on Medtronic from $84.00 to $83.00 and set a “neutral” rating for the company in a report on Thursday, June 4th. Needham & Company LLC upped their price target on Medtronic from $101.00 to $114.00 and gave the stock a “buy” rating in a research report on Thursday, August 27th. TD Cowen increased their price objective on shares of Medtronic from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Friday. Finally, Leerink Partners dropped their target price on shares of Medtronic from $117.00 to $104.00 and set an “outperform” rating for the company in a report on Thursday, June 4th. Nineteen research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $100.17.

Insider Activity at Medtronic

In other news, EVP Harry Skip Kiil sold 4,189 shares of the firm’s stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $80.44, for a total transaction of $336,963.16. Following the transaction, the executive vice president directly owned 37,227 shares of the company’s stock, valued at approximately $2,994,539.88. This trade represents a 10.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.27% of the company’s stock.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Q1 results exceeded expectations. Medtronic reported adjusted EPS of $1.45 versus the $1.39 consensus estimate, while revenue rose 13.7% year over year to $9.76 billion, topping estimates of approximately $9.55 billion. Growth was broad-based, led by cardiovascular revenue of $3.93 billion, up nearly 19% organically. Medtronic fiscal first-quarter results
• Positive Sentiment: Full-year guidance was raised. Medtronic increased fiscal 2027 organic revenue-growth guidance to 7.25%-7.75% and adjusted EPS guidance to $5.94-$6.00, with management citing strong demand for cardiovascular devices, newer growth platforms and improved margins. Medtronic raises fiscal 2027 forecast
• Positive Sentiment: Robotics expansion strengthens Medtronic’s growth strategy. The company plans to invest approximately $700 million in Hong Kong-based Cornerstone Robotics and obtain rights to distribute its Sentire surgical system in select approved markets outside the U.S. The system will complement Medtronic’s Hugo robotic platform, broadening its minimally invasive surgery offering. Medtronic Cornerstone Robotics partnership
• Positive Sentiment: Additional structural-heart investment supports future products. Medtronic will invest up to $80 million in Pi-Cardia, securing an option to strengthen its technology portfolio for complex transcatheter aortic valve replacement procedures. Analysts at William Blair reiterated a Buy rating, while BTIG raised its price target from $91 to $100.
• Neutral Sentiment: Second-quarter fiscal 2027 EPS guidance of $1.32-$1.34 was slightly below the $1.35 consensus, although full-year guidance remained broadly in line with expectations after the increase.
• Neutral Sentiment: The quarter benefited from an additional fiscal week, which contributed approximately $570 million to organic revenue, creating a comparison factor investors may monitor in coming periods.

Institutional Investors Weigh In On Medtronic

A number of hedge funds have recently made changes to their positions in MDT. Brighton Jones LLC lifted its position in shares of Medtronic by 1,368.0% during the fourth quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock valued at $3,194,000 after buying an additional 37,265 shares during the last quarter. Sivia Capital Partners LLC boosted its holdings in Medtronic by 9.6% in the second quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company’s stock worth $380,000 after acquiring an additional 381 shares in the last quarter. Strive Financial Group LLC purchased a new stake in shares of Medtronic during the fourth quarter worth about $143,000. Kelleher Financial Advisors purchased a new stake in shares of Medtronic during the third quarter worth about $126,000. Finally, Triumph Capital Management increased its stake in Medtronic by 25.1% during the 4th quarter. Triumph Capital Management now owns 887 shares of the medical technology company’s stock valued at $85,000 after purchasing an additional 178 shares in the last quarter. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).